By Watertown, Mass. – Lyra Therapeutics, a clinical-stage biotechnology company, has reported successful results from a Phase 2 study of its drug candidate, LYR-220, in patients with chronic rhinosinusitis. This inflammatory disease affects the paranasal sinuses and can significantly impact patients’ quality of life.
The study, which included adults with chronic rhinosinusitis, both with and without polyps, who had previously undergone ethmoid sinus surgery, demonstrated that LYR-220 significantly improved important patient reported outcome measures. Notably, these improvements were observed as early as two weeks into the treatment.
One of the most promising aspects of the study is the absence of any serious adverse events, indicating the drug’s safety profile. This is crucial for patients who often struggle with various symptoms associated with chronic rhinosinusitis.
These positive results have further bolstered Lyra Therapeutics’ confidence in their ongoing pivotal Phase 3 program for LYR-210. This program focuses on pre-surgical chronic rhinosinusitis patients and aims to provide additional treatment options. The company anticipates releasing topline data from this Phase 3 study in the first half of 2024.
As a result of this encouraging news, trading in Lyra shares was temporarily halted premarket on Tuesday. The company’s stock closed at $4.28 on Monday.
Comments